Quantifying Drivers of Supply Chain Resilience in Pediatric Oncology Medicines whitepaper available

Media Contact:
Anne Bell (she/her)
adb@usp.org | (240) 701-3242

Rockville – September 24, 2021 The U.S. Pharmacopeia (USP), Vizient, and Angels for Change collaborated to better characterize drug shortages through machine learning and advanced analytics. Each of the organizations independently leads efforts to strengthen the resiliency of the pharmaceutical supply chain. By combining USP’s Medicine Supply Map, Angels for Change’s network of clinical and market experts, and Vizient’s strategic sourcing and analytics expertise for essential medications, the collective team has the capability and data to explore novel drug shortage insights in the pediatric oncology space.

While the paper focuses on four factors that impact the resilience of essential pediatric oncology medicines, the analysis can be applied to other drug products and refined to fit specific use cases for government agencies, manufacturers, group purchasing organizations (GPOs), distributors, payors, and providers. The information and insights may help these groups take proactive steps to strengthen supply chains and improve patient access to quality medicines.

Download the whitepaper